Patents by Inventor Sean D. McKenna
Sean D. McKenna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11884724Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: GrantFiled: August 4, 2020Date of Patent: January 30, 2024Assignee: Merck Patent GmbHInventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
-
Publication number: 20210054073Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: ApplicationFiled: August 4, 2020Publication date: February 25, 2021Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
-
Patent number: 10759856Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: GrantFiled: March 9, 2017Date of Patent: September 1, 2020Assignee: Merck Patent GmbHInventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna, Vanita D. Sood, Gang Hao
-
Patent number: 10487147Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: GrantFiled: March 9, 2017Date of Patent: November 26, 2019Assignee: Merck Patent GmbHInventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
-
Publication number: 20170253654Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: ApplicationFiled: March 9, 2017Publication date: September 7, 2017Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
-
Publication number: 20170253653Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: ApplicationFiled: March 9, 2017Publication date: September 7, 2017Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna, Vanita D. Sood, Gang Hao
-
Patent number: 9624298Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: GrantFiled: November 21, 2012Date of Patent: April 18, 2017Assignee: Merck Patent GmbHInventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
-
Publication number: 20140341917Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: ApplicationFiled: November 21, 2012Publication date: November 20, 2014Applicant: MERCK PATENT GMBHInventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna, Vanita D. Sood, Gang Hao
-
Patent number: 7956034Abstract: FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described.Type: GrantFiled: January 16, 2007Date of Patent: June 7, 2011Assignee: Merck Serono SAInventors: Marco Muda, Xuliang Jiang, Sean D. McKenna
-
Patent number: 7820165Abstract: This disclosure relates to hybrid antigen binding molecules including at least two polypeptide chains, with at least one polypeptide chain comprises an antigen binding moiety linked to an amino acid sequence of a subunit of a heterodimeric proteinaceous hormone. Also disclosed are methods of making and using such hybrid antigen binding molecules for diagnosis and/or therapy.Type: GrantFiled: November 21, 2006Date of Patent: October 26, 2010Assignee: Merck Serono, S.A.Inventors: Sean D. McKenna, Robert K. Campbell, Xuliang Jiang, Giampiero De Luca, Meijia Yang, Christie Ann Kelton, Stephen J. Arkinstall, Chaomei He, Rene Lynn Schweickhardt
-
Patent number: 7740862Abstract: FSH mutants with increased glycosylation and longer half-lives are described. The use of FSH mutants for inducing folliculogenesis in human patients is also described.Type: GrantFiled: December 21, 2006Date of Patent: June 22, 2010Assignee: Merck Serono S.A.Inventors: Marco Muda, Xuliang Jiang, Sean D. McKenna
-
Patent number: 7700112Abstract: A novel FSH mutant with increased glycosylation and longer half-lifes for use in inducing folliculogenesis in human patients is described. The FSH mutant permits the use of lower cumulative doses of FSH to achieve the same or better clinical result.Type: GrantFiled: September 2, 2004Date of Patent: April 20, 2010Assignee: Merck Serono SAInventors: Louise M. Garone, Stephen J. Arkinstall, William H. Brondyk, Robert K. Campbell, Xuliang Jiang, Sean D. McKenna, Mark Tepper
-
Publication number: 20090130712Abstract: This disclosure relates to hybrid antigen binding molecules including at least two polypeptide chains, with at least one polypeptide chain comprises an antigen binding moiety linked to an amino acid sequence of a subunit of a heterodimeric proteinaceous hormone. Also disclosed are methods of making and using such hybrid antigen binding molecules for diagnosis and/or therapy.Type: ApplicationFiled: November 21, 2006Publication date: May 21, 2009Inventors: Sean D. McKenna, Robert K. Campbell, Xuliang Jiang, Giampiero De Luca, Meijia Yang, Christie Ann Kelton, Stephen J. Arkinstall, Chaomei He, Rene Lynn Schweickhardt
-
Publication number: 20090018070Abstract: FSH mutants with increased glycosylation and longer half-lives are described. The use of FSH mutants for inducing folliculogenesis in human patients is also described.Type: ApplicationFiled: December 21, 2006Publication date: January 15, 2009Applicant: LABORATOIRES SERONO SAInventors: Marco Muda, Xuliang Jiang, Sean D. McKenna
-
Publication number: 20080280832Abstract: FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described.Type: ApplicationFiled: January 16, 2007Publication date: November 13, 2008Applicant: Laboratoires Serono SAInventors: Marco Muda, Xuliang Jiang, Sean D. McKenna
-
Publication number: 20080213889Abstract: The present invention is directed to methods of increasing oocyte production in a mammal. More specifically, the specification describes methods and compositions for inducing follicular maturation using a PDE inhibitor. The inhibitor may be used alone at high doses. Alternatively, the follicular maturation is achieved by combining a low dose of FSH with the PDE inhibitor treatment.Type: ApplicationFiled: November 9, 2007Publication date: September 4, 2008Inventors: Stephen S. Palmer, Sean D. McKenna, Stephen J. Arkinstall, Aliza Eshkol, Michael C. MacNamee
-
Patent number: 7419999Abstract: 1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer, inflammatory disorders and other diseases and disorders associated with the prostaglandin family of compounds.Type: GrantFiled: June 9, 2003Date of Patent: September 2, 2008Assignee: Applied Research Systems ARS Holding N.V.Inventors: Gian Luca Araldi, Adulla P. Reddy, Zhong Zhao, Sean D. McKenna, Bagna Bao
-
Patent number: 7153824Abstract: The present invention is directed to methods of increasing oocyte production in a mammal. More specifically, the specification describes methods and compositions for inducing follicular maturation using a PDE inhibitor. The inhibitor may be used alone at high doses. Alternatively, the follicular maturation is achieved by combining a low dose of FSH with the PDE inhibitor treatment.Type: GrantFiled: April 1, 2004Date of Patent: December 26, 2006Assignee: Applied Research Systems ARS Holding N.V.Inventors: Stephen S. Palmer, Sean D. McKenna, Stephen J. Arkinstall, Aliza Eshkol, Michael C. MacNamee
-
Publication number: 20040259792Abstract: The present invention is directed to methods of increasing oocyte production in a mammal. More specifically, the specification describes methods and compositions for inducing follicular maturation using a PDE inhibitor. The inhibitor may be used alone at high doses. Alternatively, the follicular maturation is achieved by combining a low dose of FSH with the PDE inhibitor treatment.Type: ApplicationFiled: April 1, 2004Publication date: December 23, 2004Inventors: Stephen S. Palmer, Sean D. McKenna, Stephen J. Arkinstall, Aliza Eshkol, Michael C. MacNamee